BR112021019799A2 - Derivados contendo anéis de piridina como inibidores de malt1 - Google Patents

Derivados contendo anéis de piridina como inibidores de malt1

Info

Publication number
BR112021019799A2
BR112021019799A2 BR112021019799A BR112021019799A BR112021019799A2 BR 112021019799 A2 BR112021019799 A2 BR 112021019799A2 BR 112021019799 A BR112021019799 A BR 112021019799A BR 112021019799 A BR112021019799 A BR 112021019799A BR 112021019799 A2 BR112021019799 A2 BR 112021019799A2
Authority
BR
Brazil
Prior art keywords
derivatives containing
containing pyridine
pyridine rings
malt1 inhibitors
malt1
Prior art date
Application number
BR112021019799A
Other languages
English (en)
Inventor
Berthold Wroblowski
Jean-Claude Berthelot Didier
Stanislas M Diels Gaston
Wilhelmus John F Thuring Johannes
Tianbao Lu
Tongfei Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021019799A2 publication Critical patent/BR112021019799A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

derivados contendo anéis de piridina como inibidores de malt1. são divulgados compostos, composições e métodos para tratamento de doenças, síndromes, condições e disfunções que são afetadas pela modulação de malt 1. tais compostos são representados pela fórmula (i) como se segue, em que as variáveis são definidas aqui.
BR112021019799A 2019-04-11 2020-04-10 Derivados contendo anéis de piridina como inibidores de malt1 BR112021019799A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832608P 2019-04-11 2019-04-11
EP19178959 2019-06-07
PCT/EP2020/060307 WO2020208222A1 (en) 2019-04-11 2020-04-10 Pyridine rings containing derivatives as malt1 inhibitors

Publications (1)

Publication Number Publication Date
BR112021019799A2 true BR112021019799A2 (pt) 2021-12-07

Family

ID=70224393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019799A BR112021019799A2 (pt) 2019-04-11 2020-04-10 Derivados contendo anéis de piridina como inibidores de malt1

Country Status (12)

Country Link
US (1) US20220162187A1 (pt)
EP (1) EP3953345B1 (pt)
JP (1) JP2022528919A (pt)
KR (1) KR20210151880A (pt)
CN (1) CN113677674A (pt)
AU (1) AU2020272156A1 (pt)
BR (1) BR112021019799A2 (pt)
CA (1) CA3131856A1 (pt)
ES (1) ES2949871T3 (pt)
MA (1) MA55593A (pt)
MX (1) MX2021012417A (pt)
WO (1) WO2020208222A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス，インコーポレーテッド がんを治療する材料及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033447A2 (en) * 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
PE20170189A1 (es) * 2014-05-28 2017-03-15 Novartis Ag Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
AR106595A1 (es) * 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
US20200289514A1 (en) 2015-11-13 2020-09-17 Novartis Ag Novel Pyrazolo Pyrimidine Derivatives
CN107021963A (zh) * 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
RU2019104890A (ru) * 2016-07-29 2020-08-31 Люпин Лимитед Замещенные тиазолопиридиновые соединения в качестве ингибиторов malt1
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
JP7142022B2 (ja) * 2017-03-08 2022-09-26 コーネル・ユニバーシティー Ｍａｌｔ１の阻害剤およびそれらの使用
WO2018226150A1 (en) * 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
EA202190055A1 (ru) 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
AU2019289223B2 (en) 2018-06-18 2023-09-21 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors

Also Published As

Publication number Publication date
MX2021012417A (es) 2021-11-12
EP3953345A1 (en) 2022-02-16
ES2949871T3 (es) 2023-10-03
AU2020272156A1 (en) 2021-10-14
KR20210151880A (ko) 2021-12-14
CA3131856A1 (en) 2020-10-15
JP2022528919A (ja) 2022-06-16
MA55593A (fr) 2022-02-16
EP3953345B1 (en) 2023-04-05
WO2020208222A1 (en) 2020-10-15
CN113677674A (zh) 2021-11-19
US20220162187A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
BR112017021167A2 (pt) composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
UY38476A (es) Inhibidores de arg1 y/o arg2
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
BR112019026080A8 (pt) Composições e métodos para modular o crescimento capilar
ECSP17020172A (es) Inhibidores de histona desmetilasa
NZ728120A (en) Histone demethylase inhibitors
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
BR112021012829A2 (pt) Composições e métodos para modular o crescimento capilar
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
PH12020500300A1 (en) Compositions and methods for modulating hair growth
WO2018183370A3 (en) Kdm4 inhibitors
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BR112021019799A2 (pt) Derivados contendo anéis de piridina como inibidores de malt1
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento
BR112021008200A2 (pt) Composições e métodos para distúrbios de alfa-1-antitripsina